{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:40:14Z","timestamp":1772134814178,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["INCa-DGOS-INSERM-ITMO Cancer_18008"],"award-info":[{"award-number":["INCa-DGOS-INSERM-ITMO Cancer_18008"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1038\/s41375-024-02402-8","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T04:12:28Z","timestamp":1726114348000},"page":"2510-2513","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des My\u00e9lodysplasies (GFM) study"],"prefix":"10.1038","volume":"38","author":[{"given":"Florence","family":"Rabian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9reng\u00e8re","family":"Gruson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Th\u00e9pot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouk","family":"Walter-Petrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7027-040X","authenticated-orcid":false,"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Miguel","family":"Torregrosa-Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Toma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-2742","authenticated-orcid":false,"given":"Maud","family":"D\u2019Aveni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Delaunay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Legros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Droin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatiha","family":"Chermat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Lusina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-8766","authenticated-orcid":false,"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Sapena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8629-1341","authenticated-orcid":false,"given":"Eric","family":"Solary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-6262","authenticated-orcid":false,"given":"Raphael","family":"Itzykson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"2402_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1182\/blood-2017-04-736421","volume":"130","author":"E Solary","year":"2017","unstructured":"Solary E, Itzykson R. How I treat chronic myelomonocytic leukemia. Blood. 2017;130:126\u201336.","journal-title":"Blood"},{"key":"2402_CR2","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","volume":"2","author":"R Itzykson","year":"2018","unstructured":"Itzykson R, Fenaux P, Bowen D, Cross NCP, Cortes J, De Witte T, et al. Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. Hemasphere. 2018;2:e150.","journal-title":"Hemasphere"},{"key":"2402_CR3","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1200\/JCO.22.02699","volume":"41","author":"EN Oliva","year":"2023","unstructured":"Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, et al. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). J Clin Oncol. 2023;41:4486\u201396.","journal-title":"J Clin Oncol"},{"key":"2402_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/1078155214544076","volume":"21","author":"Y Modi","year":"2015","unstructured":"Modi Y, Shaaban H, Gauchan D, Maroules M. Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia. J Oncol Pharm Pr. 2015;21:74\u201375.","journal-title":"J Oncol Pharm Pr"},{"key":"2402_CR5","doi-asserted-by":"publisher","first-page":"e8337","DOI":"10.1097\/MD.0000000000008337","volume":"96","author":"Y Gao","year":"2017","unstructured":"Gao Y, Gong M, Zhang C, Kong X, Ma Y. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article. Medicine. 2017;96:e8337.","journal-title":"Medicine"},{"key":"2402_CR6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/bjh.17539","volume":"194","author":"T Comont","year":"2021","unstructured":"Comont T, Meunier M, Cherait A, Santana C, Cluzeau T, Slama B, et al. Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study. Br J Haematol. 2021;194:336\u201343.","journal-title":"Br J Haematol"},{"key":"2402_CR7","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.clml.2016.02.009","volume":"16 Suppl","author":"H Ramadan","year":"2016","unstructured":"Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, et al. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. Clin Lymphoma Myeloma Leuk. 2016;16 Suppl:S64\u201366.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2402_CR8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"2402_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood"},{"key":"2402_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/ejh.12393","volume":"93","author":"J Hadjadj","year":"2014","unstructured":"Hadjadj J, Michel M, Chauveheid MP, Godeau B, Papo T, Sacre K. Immune thrombocytopenia in chronic myelomonocytic leukemia. Eur J Haematol. 2014;93:521\u20136.","journal-title":"Eur J Haematol"},{"key":"2402_CR11","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3324\/haematol.2020.272559","volume":"106","author":"V Jachiet","year":"2021","unstructured":"Jachiet V, Moulis G, Hadjadj J, Seguier J, Laribi K, Schleinitz N, et al. Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Haematologica. 2021;106:1414\u201322.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02402-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02402-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02402-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T09:55:33Z","timestamp":1730282133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02402-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2402"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02402-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4113825\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"16 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RI has consulted for Amgen, BMS\/Celgene, CTI Biosciences (now Sobi) Daiichi-Sankyo, Gilead, Jazz, Karyopharm, Stemline Therapeutics (now Menarini) and Syndax, and received research funding from Abbvie and Janssen, none of which is related to the present work. LL has consulted for Amgen, BMS\/Celgene, GSK, Incyte, Novartis and Pfizer, none of which is related to the present work. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}